LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer.

It is noteworthy that abemaciclib (50 mg/kg) showed a trend of weight loss in the last few days of the experiment ( Figure 7C ) ( p < 0.05), which was not observed in the LPM3770277 treatment group ( Figure 7F ).

also in 53,322 other papers